Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaishri Blakeley

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
World Neurosurgery|November 24, 2016
Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 NeurofibromatosisJose L Porras, Wuyang Yang, Tomas Garzon-Muvdi, et al.
Elife|March 4, 2022
Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasmaAustin K Mattox, Christopher Douville, Natalie Silliman, et al.
Neurology|July 7, 2021
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based AssessmentShivani Ahlawat, K Ina Ly, Laura M Fayad, et al.
Tomography (Ann Arbor, Mich.)|January 19, 2016
Dynamic Glucose-Enhanced (DGE) MRI: Translation to Human Scanning and First Results in Glioma PatientsXiang Xu, Nirbhay N Yadav, Linda Knutsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Neuro-Oncology|August 24, 2018
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working GroupRaymond Y Huang, Wenya Linda Bi, Michael Weller, et al.
Neuro-Oncology|November 29, 2013
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastomaKaisorn L Chaichana, Ignacio Jusue-Torres, Rodrigo Navarro-Ramirez, et al.
The Laryngoscope|October 17, 2018
Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 geneD Gareth Evans, Andrew J Wallace, Claire Hartley, et al.
Investigational New Drugs|December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancerJordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.
Neuro-Oncology|May 23, 2018
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working GroupNils D Arvold, Terri S Armstrong, Katherine E Warren, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
World Neurosurgery|November 24, 2016
Surgical Treatment for Patients with Moyamoya Syndrome and Type 1 NeurofibromatosisJose L Porras, Wuyang Yang, Tomas Garzon-Muvdi, et al.
Elife|March 4, 2022
Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasmaAustin K Mattox, Christopher Douville, Natalie Silliman, et al.
Neurology|July 7, 2021
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based AssessmentShivani Ahlawat, K Ina Ly, Laura M Fayad, et al.
Tomography (Ann Arbor, Mich.)|January 19, 2016
Dynamic Glucose-Enhanced (DGE) MRI: Translation to Human Scanning and First Results in Glioma PatientsXiang Xu, Nirbhay N Yadav, Linda Knutsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2019
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular SchwannomaScott R Plotkin, Dan G Duda, Alona Muzikansky, et al.
Neuro-Oncology|August 24, 2018
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working GroupRaymond Y Huang, Wenya Linda Bi, Michael Weller, et al.
Neuro-Oncology|November 29, 2013
Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastomaKaisorn L Chaichana, Ignacio Jusue-Torres, Rodrigo Navarro-Ramirez, et al.
The Laryngoscope|October 17, 2018
Familial unilateral vestibular schwannoma is rarely caused by inherited variants in the NF2 geneD Gareth Evans, Andrew J Wallace, Claire Hartley, et al.
Investigational New Drugs|December 23, 2014
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancerJordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, et al.
Neuro-Oncology|May 23, 2018
Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working GroupNils D Arvold, Terri S Armstrong, Katherine E Warren, et al.
Pageof 6